AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biofrontera to Present at Lytham Partners Fall 2025 Investor Conference
ByAinvest
Friday, Sep 26, 2025 9:17 am ET1min read
Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will have a webcast presentation and host one-on-one meetings with investors. The webcast can be accessed through the conference home page or directly at https://app.webinar.net/wWqPp4Yr0kD. Biofrontera is a biopharmaceutical company specializing in dermatological products, including Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions.
Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event.The webcast presentation will be held at 1:15 p.m. ET on September 30, 2025. Investors can access the webcast through the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD). The webcast will also be available for replay following the event.
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development and treatment of dermatological conditions, with a particular emphasis on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK) and pre-cancerous skin lesions, which may progress to invasive skin cancers. Biofrontera is also conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.
For more information, visit [www.biofrontera-us.com](http://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet